Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

For years, the CRISPR-Cas9 genome technology has been reshaping genetic engineering, a precision tool to transform everything ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

CRISPR Therapeutics is still losing money, but it also finished March with $1.9 billion in cash after burning through $134 ...

A pivotal medical milestone has been reached. For the first time ever, researchers have used a personalized CRISPR-based gene ...

The possibility of editing our genes once seemed more like science fiction than reality. Times have changed with the ...

Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

A favorable appeals court ruling repositioned a coalition of universities and Nobel laureates to win credit for inventing a ...

The CRISPR-Cas9 patent landscape remains complex and unsettled. The Federal Circuit’s latest decision in University of California v.

The one-off treatment highlights the promise of a new type of gene editing and the challenges of using it to treat extremely ...